The second pivotal Phase 3 trial reported NOV03 consistently met primary endpoints for signs and symptoms of DED associated with meibomian gland dysfunction.

Phase 2/3 data show significant improvement in lymphoproliferation as measured by the reduction in lymph node size and increase in naïve B cells in patients with activated phosphoinositide 3-kinase delta syndrome.

The results of a comprehensive meta-analysis indicate a high prevalence of comorbidities among asthma patients, emphasizing the importance of effective treatment strategies.

Upadacitinib, a selective and reversible Janus kinase (JAK) inhibitor, may be a promising treatment option for patients with systemic lupus erythematosus.

The randomized AWARE trial indicates patients with paroxysmal AF did not have improved freedom from recurrent atrial arrhythmia with a double ablation lesion set compared with a single procedure.

SEL-212, an alternative to standard therapy that is administered once monthly, has proven to be particularly helpful for patients with severe gout, a historically underserved population.

Acute severe ulcerative colitis and a greater number of biologics precoloectomy were linked to an increased probability of acute pouchitis, while older age at colectomy was associated with a decreased probability of acute pouchitis.

New data highlighted racial and ethnic differences between patients with Merkel cell carcinoma, indicating that rates for survival were roughly similar but other distinctions remained.

On March 24, the US Food and Drug Administration announced a proposed rule changes aimed at promoting use of safe and suitable salt substitutes with the intent of improving nutrition and reducing chronic illness.

TCAs caused more examples of severe dry mouth, both objectively and subjectively, while SSRIs were associated with less severe symptoms.

A phase 2 trial comparing once weekly basal insulin Fc against once daily insulin degludec, results of the study will help provide the basis for forthcoming phase 3 research examining the agent.

New data from a systematic literature review highlighted the connection with tumor necrosis factor-α inhibitors and acne, indicating the need for further study.

No significant budget increase was observed in patients with non-radiographic axial spondyloarthritis (nr-axSpA) receiving secukinumab.

Industry payments to cardiologists remained highly prevalent in each year of study, but the research showed significant declines in the total value of payments and payment per cardiologist.

Data from a meta-analysis show late gadolinium enhancement (LGE) on cardiac MRI scans and elevated fluorodeoxyglucose (FDG) uptake on PET scans are both strong predictors of major adverse cardiac events for cardiac sarcoidosis.

An analysis of perimenopausal women with rheumatoid arthritis indicated that patients receiving exogenous sex hormones more frequently achieved SDAI- and CDAI-defined remission.

A new survey found the COVID-19 pandemic changed many Americans view of obesity and caused others to consider new weight-loss methods due to their concerns.

Data also show significant improvements in quality of life and respiratory symptoms in patients with evidence of type 2 inflammation who were treated with dupilumab.

Siperstein highlighted some more major takeaways from her conference presentation, including facts about how to determine which patients are good candidates for microneedling.

The results from the INSPIRE trial show risankizumab met all primary and secondary endpoints in treating adult patients with moderately to severely active ulcerative colitis.

New research from the Family Heart Foundation indicates high-risk patients who fail to achieve LDL-C targets had a 49% greater rate of cardiovascular events than their counterparts who met LDL-C targets.

In this interview, Siperstein explained some of the biggest takeaways from her conference presentation on advances in microneedling techniques, including radiofrequency specifically.

There was very little evidence of an effect growth or increased risk of psychiatric or neurological adverse events in the methylphenidate group compared with the no-methylphenidate group.

A 14-day randomized clinical trial assessing effects of caffeinated coffee consumption in a population of 100 adult patients, CRAVE offers what could be the most definitive insight yet into the effects of coffee consumption on overall health.

Statistical analysis showed no differences between each pairwise comparison of the bevacizumab biosimilars, MB02-SP and MB02-DM, and the reference drug.